BiotechTube
Regenovva

Regenovva

San Diego, United States· Est.
regennova.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Regennova is a private, preclinical-stage biotech founded in 2015, leveraging a peptide discovery platform to develop immune-modulating therapies for inflammatory conditions like sepsis. The company's core technology involves Apolipoprotein E (ApoE) conjugates, termed APEC, aimed at rebalancing the immune response. While the pipeline remains early-stage with placeholder product descriptions, the company has secured non-dilutive grant funding from entities like the NIH and BARDA, indicating external validation of its scientific approach. Key risks include its preclinical status, undisclosed leadership, and the highly competitive landscape of immunomodulation.

SepsisInflammatory DiseasesStroke

Technology Platform

APEC (Apolipoprotein E Conjugate) platform, a peptide discovery platform focused on leveraging ApoE as an innate immune modulator to restore immune balance in inflammatory conditions.

Opportunities

The primary opportunity lies in addressing the massive unmet need in sepsis, a condition with high mortality and no approved immunomodulatory therapies.
A successful platform could also be applied to other acute inflammatory and injury settings, such as stroke, trauma, and cytokine release syndrome, creating a broad pipeline from a single core technology.

Risk Factors

The company is at a high-risk, preclinical stage with an undisclosed leadership team and vague pipeline details.
The scientific challenge of successfully modulating the immune response in sepsis is significant, with a history of clinical failures.
Future funding beyond initial grants is not assured.

Competitive Landscape

Regennova operates in the highly competitive field of immunomodulation for acute inflammation. It faces competition from large pharma and numerous biotechs exploring targets like cytokines (IL-1, IL-6), complement inhibitors, and other immune pathways. Differentiation will require demonstrating superior efficacy or safety with its ApoE-focused approach.

More companies in Regenerative Medicine →More companies in United States →